Biomarkers.

Background: Fluid biomarkers provide a convenient way to predict AD pathophysiology. However, few studies have focused on determining associations with tau neurofibrillary tangle pathology in the early preclinical AD continuum, relevant to prevention strategies.

Methods: Ninety-nine cognitively unimpaired individuals from the ALFA+ cohort with valid F-RO-948 and F-flutemetamol PET, T1-weighted MRI, cognition, CSF, and plasma biomarkers were included.

Biomarkers.

Background: Co-morbid Alzheimer's disease (AD) pathology is a major risk factor for cognitive impairment (CI) in PD, but whether and how AD co-pathology affects the clinical phenotype of PD-CI is incompletely understood. Recently validated plasma biomarkers for AD pathology, such as ptau217, hold great promise to revolutionize the diagnosis of neurodegenerative diseases. Here, we used plasma ptau217 to detect AD co-pathology in a well-characterized cohort of PD patients with CI and examine its associations with APOE4 genotype, cognitive profile, and cerebral hypometabolism on FDG-PET.

Public Health.

Background: Cardiovascular risk factors (CVRF) are among the main modifiable risk factors for dementia in Latin America (LA). Therefore, improving cardiovascular health (CVH) is one of the main objectives of the LatAm-FINGERS trial, the largest non-pharmacological (lifestyle improvement) randomized trial in LA. But, to fully comprehend CVH it is necessary to explore its relation with the social determinants of health (SDH), that are closely associated with lifestyle.

Biomarkers.

Background: Plasma phosphorylated tau (p-tau), particularly p-tau217, has demonstrated its reliability as a biomarker for diagnosing Alzheimer's disease (AD). Coming challenges in the field include determining whether quantifying additional plasma phosphorylated, and non-phosphorylated tau species could enhance diagnostic accuracy, prognosis, and improve patient monitoring by effectively staging the disease.

Method: We used a mass spectrometric targeted method to simultaneously quantify the levels of six different phosphorylated (p-tau 181, 199, 202, 205, 217 and 231), and six non-phosphorylated (0N CNS-specific, 1N CNS-specific, tau195-209, tau212-221, PNS-specific 7-14, PNS-specific 151-167) tau peptides in plasma.

Alzheimer's Imaging Consortium.

Background: Fluid biomarkers provide a convenient way to predict AD pathophysiology. However, few studies have focused on determining associations with tau neurofibrillary tangle pathology in the early preclinical AD continuum, relevant to prevention strategies.

Methods: Ninety-nine cognitively unimpaired individuals from the ALFA+ cohort with valid 18F-RO-948 and 18F-flutemetamol PET, T1-weighted MRI, cognition, CSF, and plasma biomarkers were included.